Sunday, September 13, 2026
28.4 C
Bengaluru

Indian Pharma Market October 2021 – IQVIA Report

IPM was valued at Rs. 178,219 Cr for MAT Oct’21. The retail sector was valued at Rs. 151,183 Cr for this period contributing 85% to IPM.

IPM Growth for the month of Oct’21 as compared to the month of Oct’20 was 9.7%. This is the lowest monthly growth in the last 8 months after a low growth of 2.6% reported for Feb’21.

Corresponding to low monthly growth, IPM MAT growth also declined slightly after showing a growing trend consistently for the last 7 months from MAT Feb’21. It reported 17.3% for MAT Oct’21 as compared to 17.8% reported for MAT Sept’21.

At 15657.3 Cr, the monthly sale reported for Oct’21 is the 5th highest sale value in the last 12 months.

Free Membership Required

You must be a Free member to access this content.

Join Now

Already a member? Log in here

Hot this week

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

How wearables, diagnostics, AI and continuous monitoring are moving...

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

RPG Active Pharma’s agreement to acquire the API and...

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It...

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

India has two very different pharmaceutical regulators living inside...

MedicinMan Pharma Pulse: August 2026

🚀 The Mega-Merger That Wasn't Early August saw the...

Topics

The Great Healthcare Pivot: Who Owns The Consumer Before They Become A Patient?

How wearables, diagnostics, AI and continuous monitoring are moving...

RPG-Raghava and Lessons From a Decade of Indian Pharma M&A

RPG Active Pharma’s agreement to acquire the API and...

Pharmacy of the World Pricing Paradox

India occupies an extraordinary position in global pharmaceuticals. It...

Why The Government Must Stop Playing Market Trader And Start Being The Sheriff

India has two very different pharmaceutical regulators living inside...

MedicinMan Pharma Pulse: August 2026

🚀 The Mega-Merger That Wasn't Early August saw the...

GLP-1: When the Molecule Becomes a Commodity, What Becomes the Moat?

STOP PRESS August 10, 2026: Regulatory Authorisation — The UK...

How To See Dr Reddy’s Nestle In The Wellness Shift

GLP-1 medicines such as semaglutide and tirzepatide are changing...

How To Power The India Biopharma Regulatory Revolution Now

Beyond the Pharmacy of the World: Why India's Biopharma...
spot_img

Related Articles

spot_imgspot_img